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Supporting Information for  
 
Next-generation sequencing for the diagnosis of MYH9-RD 
 
 
Supplemental methods 
Protein modelling 
Protein structure homology modelling was performed using the SWISS-MODEL 
workspace (Biasini, et al 2014). The SWISS-MODEL template library (SMTL version 
2017-02-01, PDB release 2017-01-26) was searched with Blast and HHBlits for 
evolutionary related structures matching the target sequence. Results are shown using 
the myosin 2 heavy chain template (amino acids 1-959). There is no model from amino 
acid 960 to 1960 due to the lack of homology with any other protein. 
 
 
DNA extraction and Sanger sequencing 
Peripheral venous blood was collected at over 100 hospitals by Hematologists with an 
interest in inherited BPDs and sent to the Cambridge Translational GenOmics (CATGO) 
laboratory in Cambridge (UK) in EDTA tubes. Genomic DNA was extracted and quantified 
using PicoGreen (ThermoFisher Scientific Inc., MA, USA). All variants described in this 
paper were confirmed by Sanger sequencing. Primers were designed using PRIMER3 
and the amplification carried out in a GeneAmp PCR System 9700 using 10ng DNA. 
Amplicons were purified by using QIAGEN (QIAGEN, Venlo, The Netherlands) columns 
and sent for Sanger sequencing to Source BioScience (Source BioScience, UK). Ethics 
authorities and approval numbers are provided in Table S1. 
 
Immunofluorescence  
Immunofluorescence analysis was performed by two independent centres. In center 1, 
blood smears were fixed and permeabilized with ice cold acetone for 3 minutes, blocked 
with 1% BSA for 1 hour and incubated with a rabbit-anti human NMMHCIIA antibody 
(Sigma Aldrich, M8064) and an Alexa-Fluor® 488 conjugated secondary antibody (Life 
Technologies). Nuclei were stained with Hoechst. Specimens were mounted with the 
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ProLong Antifade medium (Molecular Probes) and analyzed at room temperature by a 
Carl Zeiss Axio Observer.A1 fluorescence microscope (Carl Zeiss Inc, Oberkochen, 
Germany). 
In centre 2, blood smears were fixed with acetone for 2 min and blocked with goat serum 
donor herd (Sigma G-6767, St. Louis, US) followed by staining with an anti-NMMHCIIA 
(Sigma Aldrich M8064 St. Louis, US) followed by Alexa Fluor 488 (Thermofisher, 
Waltham, US). Fluorescence micrographs were acquired on Leica TCS SP5 (Leica, 
Wetzlar, Germany) laser scanning confocal microscope with a HCX PL APO 40.0x 
N.A.1.25 oil immersion objective. Alexa Fluor 488 was excited by a 561nm DPSS laser. 
Pinhole was set to 67.9 µm (1 Airy Unit) and emission was collected by PMT 2 (508nm - 
540nm). Image processing and analysis was performed on Bitplane Imaris version 7.6.5 
(Bitplane, Switzerland). 
 
Gene expression analysis 
BLUEPRINT RNA sequencing data (http://dcc.blueprint-epigenome.eu/#/datasets) were 
downloaded from EGA and processed as follow: 
Trim Galore 0.3.7 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with 
parameters “-q 15 -s 3 --length 30 -e 0.05” was used to trim PCR and sequencing 
adapters off. Trimmed reads were then aligned to the Ensembl v.70 human transcriptome 
using Bowtie 1.0.1 (PMID: 19261174) with parameters “-a --best --strata -S -m 100 -X 
500 --chunkmbs 256 --nofw --fr”.  MMSEQ 1.0.8a with default parameters2,3 was used to 
quantify (gene and) transcript expression. Mmdiff with parameters “-fixalpha -p 0 -uhfrac 
1.0” was used to summarise and normalize (gene and) transcript expression for cell type. 
 
Sequencing and bioinformatics pipeline  
Genome Sequencing was performed using the Illumina TruSeq DNA PCR-Free Sample 
preparation kit (Illumina, Inc.) and an Illumina HiSeq 2000 or HiSeq-X, generating a 
minimum coverage of 15x for approximately 95% of the genome (see also 
http://iovs.arvojournals.org/article.aspx?articleid=2503479). Targeted sequencing was 
performed using an Illumina HiSeq2500 or HiSeq4000 generating a minimum coverage 
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of 20x for approximately 99.99% of the targeted regions (with an average coverage of 
833+193 reads for the MYH9 gene). Reads were aligned to the Genome Reference 
Consortium human genome build 37 (GRCh37) using the Isaac Genome Alignment 
Software (HAS2: http://support.illumina.com/sequencing/sequencing_software/hiseq-
analysis-software-v2-0.html).  Genome VCF files 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137218/) were merged with Illumina 
AGG3 software (https://github.com/Illumina/agg).  Structural Variants (SVs) were 
identified in the individuals who had genome sequencing using two independent 
algorithms: Isaac Copy Number Variant Caller (Canvas, Illumina), which identifies copy 
number gains and deletions based on read depth, and Isaac Structural Variant Caller 
(Manta, Illumina), which identifies translocations, deletions, tandem duplications, 
insertions, and inversions based on both paired read fragment spanning and split read 
evidence.  
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Supplemental Tables 
 
Table S1. Ethics authorities and approval numbers 
 
Name of national ethics authority 
responsible Ethics approval number Country 
Cambridgeshire 1 Research Ethics 
Committee 
10/H0304/66 UK 
Ethics Committee of the University 
Hospital Leuven 
ML3580 Belgium 
Children’s Hospital of Philadelphia 
Institutional Review Board  
IRB#12-008603 USA 
Beth Israel Deaconess Medical 
Center IRB 
Protocol #: 2011P000337 USA 
Ethics Board of the University of 
Perugia 
2014-031 Italy 
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Table S2. Patients excluded from this study. BPD= bleeding and platelet disorders; MPV= 
mean platelet volume 
 
Patient 
Transcript 
NM_002473.5 
Protein 
NP_002464.1 
Reason of exclusion 
 
51 
 
c.906C>G 
p.(Phe302Leu) 
Abnormal platelet function and abnormal dense 
granules. Normal platelet volume (MPV: 8.8 fl), platelet 
count 358x109/L. 
           52 c.1724G>T 
p.(Gly575Cys) 
 
Cornelia De Lange Syndrome. 
Normal platelet volume (MPV:7.6 fl). 
53 c.1747G>A 
p.(Asp578Tyr) Normal platelet volume (MPV: 10 fl). 
 
54 c.2344G>A 
p.(Val782Ile) 
Ehler-Danlos syndrome. Normal platelet volume, MPV: 
10.3 fl, platelet count 203x109/L. This variant is also 
present in one non-BPD patient. 
55 c.2403G>T 
p.(Lys801Asn) 
This case was explained with the presence of a 
pathogenic variant in another gene. 
56 c.2708G>A 
p.(Arg903Gln) 
Ehler-Danlos syndrome. Normal platelet volume (MPV: 
8.3 fl), platelet count 710x109/L. 
57 c.2912C>T 
p.(Ala971Val) 
Platelet storage pool disease, normal platelet volume 
(MPV: 10.2 fl), platelet count 262x109/L. 
 
58 c.2965A>C p.(Lys989Gln) 
This variant is present in one non-BPD patient and 
absent in the affected mother. Platelet count 217x109/L. 
 
       59/60/61 
c.3340T>C 
p.(Ser1114Pro) This variant is present in five non-BPD patients. 
 
62 c.3677G>A p.(Arg1226Gln) 
 
This case was explained with the presence of a 
pathogenic variant in another gene. 
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63 c.3817G>A 
p.(Asp1273Asn) This variant is present in three non-BPD patients. 
 
64/65/66/67/68 c.4225G>A p.(Asp1409Asn) 
This variant is present in 15 non-BPD patients. Normal 
platelet volume (MPV:8 fl). 
 
69 
c.4330A>C 
p.(Lys1444Gln) Normal platelet volume  (MPV: 7.2 fl). 
 
70 c.4439C>G 
p.(Ser1480Trp) Platelet function disorder. Normal platelet volume. 
 
 
71 c.4529T>G 
p.(Met1510Arg) 
Patient has macrothrombocytopenia, however this 
variant is present in the healthy mother. Negative for 
MYH9 aggregates at immunofluorescence analysis and 
with low  conservation score. 
 
72 c.4774C>T 
p.(Arg1592Trp) 
This case was explained with the presence of a 
pathogenic variant in another gene. 
 
73 c.4955G>A p.(Arg1652His) Normal platelet volume (MPV: 7.7 fl). 
74 c.5328C>A 
p.(Asn1776Lys) Thrombotic patient with thrombocytosis. 
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Table S3. Centralized analysis of blood smears for the identification of Döhle-like 
inclusion bodies in patients with previously not performed or negative detection of 
Dohle-like inclusion bodies. Patients not listed in the table had the Döhle-like bodies 
previously detected by MGG-staining. n/a= not available; VUS= Variant of Uncertain 
Significance; MGG= May-Grünwald-Giemsa; IF= Immunofluorescence. * = represents 
the 18 patients available for the centralized analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patien
t 
Transcript 
NM_002473.5 
Protein 
NP_002464.1 
Variant 
classification 
Detection 
of Dohle 
like bodies 
from the 
submitting 
center 
Result from 
centralized 
analysis 
(MGG) 
Result 
from 
centralized 
analysis 
(IF) 
Type of 
NMMIIA 
inclusion 
 
1* 
c.97T>G 
p.(Trp33Gly) 
Likely 
pathogenic absent present present II 
 
5 
c.279C>G 
p.(Asn93Lys) Pathogenic absent n/a n/a n/a 
 
6* 
c.283G>A 
p.(Ala95Thr) Pathogenic absent present present III 
 
7* 
c.287C>T 
p.(Ser96Leu) Pathogenic absent uncertain present III 
 
9 
c.287C>T 
p.(Ser96Leu) Pathogenic absent n/a n/a n/a 
 
10* 
c.287C>T 
p.(Ser96Leu) Pathogenic absent uncertain present III 
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11* 
c.1119G>C 
p.(Lys373 Asn) 
Likely 
pathogenic uncertain present present II 
     12 c.2104C>T p. (Arg702Cys) Pathogenic absent n/a n/a n/a 
 
13 
c.2104C>T 
p.(Arg702Cys) Pathogenic absent n/a n/a n/a 
 
14* 
c.2152C>T 
p.(Arg718Trp) Pathogenic absent uncertain present III 
 
15* 
c.2152C>T 
p.(Arg718Trp) Pathogenic absent uncertain present III 
 
16* 
c.2152C>T 
p.(Arg718Trp) Pathogenic absent present present III 
 
18* 
 
c.2507C>T 
p.(Pro836Leu) 
Likely 
pathogenic absent present 
Poor 
quality 
sample 
n/a 
 
19* 
 
c.2507C>T 
p.(Pro836Leu) 
Likely 
pathogenic absent present present III 
 
20* 
c.2668delC 
p.(Gln890Argfs
Ter) 
VUS absent present present III 
 
22 
 
c.3493C>T 
p.(Arg1165Cys
) 
Pathogenic absent n/a n/a n/a 
 
23 
 
c.3493C>T 
 
p.(Arg1165Cys
) 
 
 Pathogenic absent n/a n/a n/a 
 
24 
 
c.3493C>T 
 
p.(Arg1165Cys
) 
Pathogenic absent n/a n/a n/a 
 
26* 
 
c.3493C>T 
 
p.(Arg1165Cys
) 
Pathogenic absent present 
Poor 
quality 
sample 
n/a 
 
27 
 
c.3493C>T Pathogenic absent n/a n/a n/a 
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p.(Arg1165Cys
) 
28* c.3584C>T  p.(Ser1195Leu) VUS absent absent present III 
29* c.4262A>C p.(Glu1421Ala) VUS absent uncertain present III 
 
30* 
c.4270G>A 
 
p.(Asp1424Asn) 
Pathogenic absent present present II 
 
32* 
 
c.4270G>A 
 
p.(Asp1424Asn) 
Pathogenic absent present present II 
 
34 
c.4270G>T 
p.(Asp1424Tyr) Pathogenic absent n/a n/a n/a 
 
35 
c.4270G>T 
p.(Asp1424Tyr) Pathogenic absent n/a n/a n/a 
37  c.4302G>C p.(Gln1434His) VUS absent n/a n/a n/a 
 
39* 
c.2761G>A 
 and 
c.4946A>G 
p.(Glu921Ly) 
and 
p.(Asp1649Gly) 
VUS absent present 
Only MGG 
stained 
smear 
available 
n/a 
40* c.5032A>G p.(Met1678Val) VUS absent uncertain present III 
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Table S4. Severity of thrombocytopenia. A) Distribution of platelet count 
measurements in the cohort. Y axis: number of patients; X axis: platelet count. B) 
Platelet count per patient. Patients were divided in three groups according to platelet 
count. Patients were numbered from 1 to 50. In brackets, the corresponding platelet count 
are reported. Underlined and in italic the two cases with no thrombocytopenia but large 
platelets. Both automated and microscopic platelet counts are shown. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
Platelet count (x109/L) < 20 20 - 50 >50 
 
Patient (automated 
platelet count ) 
1(15); 4(8); 12(17); 
33(11); 50(16) 
2(46); 3(21); 5(21); 6(25); 8(21); 
10(40); 11(45); 22^(46); 25(22); 
28(20); 30(20); 32(37); 34ᐤ(22); 
36(47); 41(50); 42(20); 43ᐥ(50); 
44ᐥ(47); 46(26); 
7(121); 9(120) 
13(74);14#(122); 15#(117); 
16#(118); 17#(187); 18(138); 
19(81); 20(88); 21(70); 
23(53); 24^(61); 26(62); 
27(67); 29(60); 31(99); 
35ᐤ(61); 37(96); 38(68); 
39(95); 40(220); 45(106); 
47(59); 48(86); 49(54) 
Patient  
(optical platelet count) 
28(3) 3(25); 5(41); 43(50); 44(47) 2(80); 38(68); 48(86) 
Members of the same family are identified with the following symbols: # (17 index case, 14 sister, 15 nephew, 16 
mother) ^ (22 index case, 24 father), ᐤ (34 index case, 35 mother),  ᐥ (44 index case, 43 daughter). 
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Table S5. Laboratory test results. Laboratory test results are displayed in this table. 
APTT = Activated Partial Thromboplastin time ; PT = Prothrombin Time; FBC = full blood 
count; RBC = red blood cell; HGB = haemoglobin; BASO = basophils; NEUT = 
neutrophils; LYMPH = lymphocytes; MPV = mean platelet volume; N/A = Not Applicable 
  
Patient Gender Age at 
presentation 
(years old) 
APTT 
(sec) 
PT 
(sec) 
FBC.RBC (x10e12/L); 
FBC.HGB (g/dl); 
FBC.BASO (x10e9/L);) 
FBC.NEUT (x10e9/L); 
FBC.LYMPH (x10e9/L); 
MPV (fL) 
1 F 2 21.8 11.3 4.39; 14.5; 0.0; 3.0; 1.6; N/A 
2 M 31   N/A  N/A N/A 
3 M 14 24.1 11.3 N/A; N/A; N/A; N/A; N/A; 16 
4 F 3 N/A N/A 3.54; 10.3; 0.3; 6.15; N/A 
5 M 30 N/A N/A N/A; N/A; N/A; N/A; N/A; 14.5 
6 M  2 N/A N/A 4.48; 12.4; 0; 4.4; 6.2; N/A 
7 M  N/A  N/A  N/A N/A; N/A; N/A; N/A; N/A; 14.1 
8 F  60  N/A  N/A 4.77; 14.2; 0; 8.6; 2.4; N/A  
9 F 0  N/A  N/A N/A; 12.2; N/A; N/A; N/A; 10.1 (note from 
clinician: macrothombocytopenia on 
examination of the smear) 
10 M 0 N/A N/A 4.84; 13.9; N/A; N/A; N/A; N/A 
11 F 56   N/A  N/A N/A 
12 F 7  N/A  N/A 4.17; 11.6; 0.1; 1.9; 3.7; N/A 
13 F 11 29.8 10 4.8; 13.5; 0.03; 6.5; 1.3; 10 (note from 
clinician: macrothombocytopenia on 
examination of the smear)  
14 F 54 29.3 10.8 4.74; 14.4; 0.03; 3.24; 1.92; 15.1 
15 F N/A  N/A  N/A 4.67; 13.6; 0.03; 2.7; 2.21; 16 
16 F N/A N/A N/A 4.89; 15.4; 0.03; 8.15; 0.84; 15.1 
17 F N/A N/A N/A 4.64; 13.6; 0.07; 3.24; 1.79; 14.6 
18 F 33  N/A N/A N/A;N/A;N/A;N/A;N/A; 14.5 
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19 M 38  N/A N/A N/A 
20 M 86 25.8 12.3 4.3; 13.5; 0.03; 4.34; 0.8; N/A 
21 F 5  N/A N/A  N/A 
22 M  21  N/A  N/A 5.24; 15.3; 0.02; 1.97; 1.48; N/A 
23 F  N/A N/A   N/A N/A 
24 M  45  N/A N/A  5.18; 15; 0.04; 3.65; 1.27; N/A 
25 F  31 27.8 9.7 4.3; 12.4; 0; 2.9; 0.8; N/A 
26 M 58  26.2 10.2 4.62; 14.4; 0.05; 2.01; 1.20; 20.2 
27 F 19 30.5 11.9 4.65; 14.5; 0.06; 3.33; 2.37; N/A 
28 M  2  N/A  N/A 4.3;12;N/A;N/A;N/A;not detected by 
electronic counter 
29 M  N/A  N/A  N/A N/A 
30 M 19 34.8 12.3 5.29; 13.6; 0; 1.8; 1.2; 8.2  (note from 
clinician: 8.2  is the automated count, 
macrothombocytopenia on examination of 
the smear) 
 
31 M  2 N/A   N/A 4.44; 12; 0.1; 5.1; 6.3; 13.6 
32 M 10  N/A  N/A N/A; 15.1; N/A; N/A; N/A; N/A 
33 F N/A N/A N/A 4.47; 11.2; N/A; N/A; N/A; 11 
34 F 22 19.7 10.1 6.0; 14.6; 0.03; 3.14; 1.03; N/A 
35 F 43 26.4 12.3 4.98; 13.9; 0.07; 4.03; 1.95; N/A 
36 F 27 N/A N/A N/A 
37 F N/A  24 10.6 5.47; 11.3; N/A; N/A; N/A; N/A 
38 M 0 24.2 12.1 5.43; 14.6; 0; 7.5; 4; 13.8 
39 M 30 26.3 10.1 5.48; 15.7; 0.03; 2.6; 1.56; 17.3 
40 F 15 26.9 10.5 4.97; 13.6; 0; 2.9; 1.9; 12.2  
41 F  56  N/A  N/A N/A 
42 F  22  N/A  N/A N/A 
43 F 16 23.1 11.9 4.37;12.7; 0; 1.1;1.8; 12.8 
44 F 48 25.6 12.3 4.28; 12.1; 0; 4.8; 3.1; 13.3 
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45 F 29 N/A N/A N/A 
46 M 18  N/A  N/A 5.02; 14.8; 0; 1.5; 1.6; N/A 
47 F 46  N/A  N/A 4.06; 12.3; 0.03; 2.78; N/A; N/A 
48 M 20 23.2 12.2 3.85; 11.8; 0; 0.2; 2; 12.5 
49 M 2 24.2 10.4 N/A; 11.5; 3.13; 0.03; 2.98; N/A 
50 F 8  N/A  N/A N/A 
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Table S6. Bleeding score. Patients were classified according to the 12 major symptoms 
within the MCMDM-1 VWD Bleeding Assessment Tool with scores from -1 to 4. Total 
bleeding score are shown for females and males. Bleeding score is considered normal if 
less than 3 and 5 for males and females, respectively.  
 
Bleeding Phenotype 
score 
-1 1 2 3 4 
CNS bleeding           
Cutaneous   5, 6*, 7, 10, 12, 18, 
21, 22, 23, 25*, 28, 
41, 43, 44, 46*, 47, 
48, 49 
1, 9, 16, 
37,38 
    
Epistaxis   1, 18, 22, 24, 26, 
28, 33, 40, 41,42, 
43, 44, 46*, 50 
14, 15,  16, 21, 
30, 47 
  
From minor wounds   1, 18, 22, 30, 43, 
44, 45* 
9, 47     
Haemarthrosis           
Menorrhagia   4, 8*, 43 1, 18, 37  13, 40 17, 21, 34, 
47 
Muscle Haematomas   24, 47       
Oral cavity   46*, 47  14     
Postpartum 
haemorrhage 
13, 14, 
16, 37, 
47 
44  17  40   
Surgery or major trauma 13, 14, 
17, 41, 
47 
8*  2, 5 30 16, 20  
Tooth extraction 13, 14, 
15, 16, 
17, 21, 
24, 37 
8, 30, 40, 44, 45  34, 38     
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Total Bleeding 
Score  
BS=0  BS 1-5 BS≧6 
Female cases 11, 13, 27, 29, 35, 36 4, 8, 9, 12, 14, 15, 17, 
18, 23, 25, 33, 37, 41, 
42, 43, 44, 45, 50 
1, 16, 21, 34, 40, 47 
General Bleeding    
Severity 
BS=0  BS 1-3 BS≧4 
Male cases 3, 19, 31, 32, 39  2, 5, 6, 7, 10, 22, 24, 
26, 28, 46, 48, 49 
20**, 30**, 38 
  
* 6, 8, 25, 45, 46 are patients with no calculated bleeding score. The  bleeding score has been 
assigned according to the clinical synopsis provided. 
**prolonged bleeding after surgery 
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Table S7. Hearing impairment, renal and liver dysfunctions screening. 
nv= normal values 
 
Patie
nt Hearing impairment    Renal dysfunction  Liver 
8 Complete deafness (the patient only communicates via sign language) 
Mild proteinuria.  
Total protein loss in urine/24 hour: 2.06 g/24 h 
(nv <= 0.15 g/24 h); albumine/creatine ratio: 1520 
mg/g creatinine (nv < = 30); microalbumine 506 
mg/L (nl <= 20); microalbumine 1772 mg/24 h (nv 
<=30) 
No dysfunction 
10 
Bilateral mild to moderate neurosensorial 
hearing loss (audiometric examination 
included tonal audiometry, logo-audiometry 
and tympanometry). 
Mild proteinuria. Total protein loss in urine/24 
hours: 0.3 g/24h (nv <= 0.15g/24 h). Serum 
creatinine: 0.62 mg/dL (normal range for age: 
0.6–1.1 mg/dL); glomerular filtration rate (GFR): 
80 mL/min/1.73m (normal range for age>75 
mL/min/1.73 m).  
No dysfunction 
12 Clinically manifested hypoacusia No dysfunction No dysfunction 
17 No dysfunction Renal anatomic abnormality (horseshoe kidney, not related to MYH9-RD). Normal albumin. No dysfunction 
18 
Mild high frequency sensorineural 
deafness. Audiograms: 60 dB at 4 kHz. 
Bilateral hearing aids used intermittently. 
No dysfunction 
Mildly elevated ALT (61-94 IU/L, 
(normal range 10-50). Bilirubin, 
ALP, albumin within normal 
limits.  
34  Clinically manifested hypoacusia  No dysfunction No dysfunction 
35  Clinically manifested hypoacusia  No dysfunction No dysfunction 
36 
Patient had full audiological work-up, 
demonstrating mild high frequency 
sensorineural hearing impairment. Bilateral 
hearing aids used intermittently. 
No dysfunction No dysfunction 
38 Bilateral mild neurosensorial hearing loss for acute frequencies (audiograms). No dysfunction 
GTP=73 (normal values <45); 
GOT=53 (normal values<45); 
ALP =1880 (normal values<320); 
gamma-GT=36 (normal values 
<45) 
43 
Sensorineural drop right ear at 8KHz; 
normo-acusia left ear. No clinically 
manifested hypoacusia (audiograms). 
No dysfunction No dysfunction 
44 
Bilateral mild to moderate sensorineural 
hearing loss for acute frequencies 
(audiograms). 
 
No dysfunction No dysfunction 
48 Severe bilateral sensorineural hearing loss for mid-high frequencies (audiograms). No dysfunction No dysfunction 
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Supplemental Figures 
 
Figure S1. MYH9 protein structure model.  
 
A. Protein structure homology model for MYH9. Results are shown using the myosin 2 
heavy chain template (amino acids 1-959). From amino acid 960 to 1960 it is not possible 
to establish a model due to the lack of homology with any other protein. B. SH3/MD 
interface. C. In red, the amino acid in position 33 involved in the W33G variant is shown 
in the SH3/MD interface D. In red, the amino acid in position 41, involved in the F41S 
variant in the SH3/MD interface. 
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Figure S2. Coverage of the 12 novel variants. A) Whole Genome Sequencing (WGS) 
read coverage. Coverage plots for the five WGS cases. Case 39 has two novel variants. 
Mean read coverage 69X. B) Targeted sequencing read coverage. Coverage plots for 
the seven cases enrolled on the targeted ThromboGenomics platform. Mean read 
coverage 2300X. First and last exons highlighted.  
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Figure S3. Expression levels of MYH9 transcripts across different blood cell types. 
Normalised expression of MYH9 transcripts in platelets (Plat), megakaryocytes (MK), 
erythroblasts (EB) and neutrophils (Neut) obtained from venous blood and cord blood, in 
dark and light green, respectively. Cell types are represented in brown for platelets, ochre 
for megakaryocytes, pale yellow for erythroblasts and grey for neutrophils. The top three 
rows show the expression level of the protein coding transcripts (rectangles with red, pink 
and pale pink on the left of the main panel). In the same column, in grey, the non-coding 
protein transcripts. ENST00000216181 (NM_002473.5) is the full length transcript (7501 
bp, 1960 aa). High relative expression is shown in red and low relative expression in blue 
according to log2(FPKM+1). 
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Figure S4. Phenotype-genotype correlation. The x axis indicates the exons of the 
MYH9 gene with one or more variants found in this cohort and the y axis shows the 
number of patients with a specific phenotype. Patient 39 is represented twice due to the 
presence of two variants in exons 22 and 33. Patient 2 has been reported with a platelet 
count of 46x109/L and 80x109/L. In this graph patient 2 has been included to the group of 
patients with platelet count >50x109/L. 
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Figure S5. Distribution of bleeding tendency and platelet count. Patients have been 
divided in three groups according to their bleeding scores: no bleeding (BS=0), normal 
bleeding (BS= 1-5 for female or BS= 1-3 for male), excessive bleeding (BS>6 for female 
or BS>4 for male). No significant correlation has been found. Further details on bleeding 
score calculation can be found in Materials and Methods. BS= Bleeding Score; square= 
male patient; circle= female patient;  
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Figure S6. NMMHC-IIA localization and Döhle-like inclusion bodies analysis           for 
the p.Gln890ArgfsTer variant. Light microscopy (A) and immunofluorescence (B) 
analyses of granulocytes in patient 20 show a non classical distribution of NMM-IIA, with 
some small punctuate clusters. 
                
 
